文献速递其他结缔组织病

阿维西胍:一种新型可溶性鸟苷酸环化酶激活剂,影响多种细胞类型以抑制干扰素-1信号传导和纤维化

Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该临床前研究在系统性硬化症(SSc)模型中表征新型可溶性鸟苷酸环化酶激活剂阿维西胍。阿维西胍减少缺氧诱导的内皮细胞TGF-β2合成、抑制血小板释放CXCL4,并在博来霉素诱导的皮肤和肺纤维化小鼠中显示抗纤维化作用。RNA测序显示阿维西胍较利奥西胍更深入地调控干扰素-1信号和免疫相关基因。

要点

  • 阿维西胍减少缺氧诱导的HMVEC-d合成TGF-β2并抑制血小板释放CXCL4。
  • 阿维西胍在博来霉素诱导的小鼠皮肤和肺纤维化中显示抗纤维化作用。
  • 阿维西胍较利奥西胍更深入调控IFN-1信号和免疫相关基因。

核心结论

  • 临床前研究表明阿维西胍有潜力影响小鼠SSc模型中的血管、纤维化和免疫相关过程。
  • 这些研究提示阿维西胍可能对SSc病理生理的多个方面提供治疗益处,并支持进一步在II期临床试验(VITALISScE™;NCT05559580)中研究阿维西胍治疗SSc的依据。

研究设计与样本

  • 在人微血管内皮细胞-真皮(HMVEC-d)缺氧培养和活化的人富血小板血浆中,加入不同剂量的阿维西胍,分别检测TGF-β2和人CXC趋化因子家族配体4(CXCL4)水平。
  • 在博来霉素诱导的皮肤和肺纤维化小鼠中分析阿维西胍治疗。

主要发现

  • 阿维西胍减少HMVEC-d缺氧诱导的TGF-β2合成,并抑制血小板释放CXCL4。
  • 阿维西胍在博来霉素诱导的皮肤和肺纤维化中显示抗纤维化作用。
  • 受累皮肤的RNA测序发现阿维西胍与利奥西胍不同的独特表达谱。
  • 与利奥西胍治疗相比,阿维西胍治疗导致对IFN-1信号及免疫反应相关基因更深入的调控。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The soluble guanylate cyclase (sGC) stimulator riociguat is approved for the treatment of pulmonary arterial hypertension and may have antifibrotic effects. However, in fibrotic tissues, oxidative stress and hypoxia can render sGC insensitive to sGC stimulators. sGC activators overcome this limitation. Here, we characterize the novel sGC activator, avenciguat, in preclinical models of SSc. METHODS: Human microvascular endothelial cells-dermal (HMVEC-d) cultured in hypoxic conditions and activated human platelet-rich plasma were incubated with varying doses of avenciguat, and the levels of TGF-β2 and human CXC chemokine family ligand 4 (CXCL4) were measured, respectively. Treatment with avenciguat was analysed in mice with bleomycin-induced dermal and pulmonary fibrosis. RESULTS: Avenciguat reduced hypoxia-induced synthesis of TGF-β2 by HMVEC-d and inhibited CXCL4 release by platelets. Moreover, avenciguat demonstrated antifibrotic effects on bleomycin-induced dermal and pulmonary fibrosis. RNA sequencing of affected skin uncovered a unique profile distinguishing avenciguat from riociguat. Avenciguat treatment resulted in deeper regulation of IFN-1 signalling and genes associated with immune response vs riociguat treatment. CONCLUSION: In preclinical studies, avenciguat shows the potential to influence vascular, fibrotic and immune-related processes in murine models of SSc. These studies suggest that it may offer therapeutic benefit across multiple aspects of SSc pathophysiology and support the rationale for further investigation in a Phase II clinical trial (VITALISScE™; NCT05559580) of avenciguat in SSc.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kaufman J, Nabozny G, Tran-Manh C, et al. Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis. Rheumatology (Oxford). 2025. PMID: 39985455. doi:10.1093/rheumatology/keaf109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。